NYSE$PFE
Pfizer · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported strong Q4 and full-year 2021 financial results, provided 2022 financial guidance, and raised Comirnaty revenue guidance while issuing Paxlovid revenue guidance.
Pfizer reported a strong fourth quarter with revenues of $23.8 billion, a 105% increase compared to the prior-year quarter. The company provided full-year 2022 revenue guidance of $98.0 to $102.0 billion and adjusted diluted EPS of $6.35 to $6.55. Pfizer also raised its Comirnaty revenue guidance to approximately $32 billion and issued initial Paxlovid revenue guidance of approximately $22 billion for 2022.
- Q4 2021 revenues reached $23.8 billion, reflecting a 106% operational growth.
- Reported diluted EPS for Q4 2021 was $0.59, while adjusted diluted EPS was $1.08.
- Full-year 2021 revenues amounted to $81.3 billion, demonstrating a 92% operational growth.
- Pfizer issued full-year 2022 revenue guidance of $98.0 to $102.0 billion and adjusted diluted EPS guidance of $6.35 to $6.55.
Headline financials
Revenue & EPS history
Pfizer · Revenue · Quarterly
$23.8B
Revenue by segment
Pfizer · $23.8B total across 2 segments · Q4 2021
- Biopharma$23.5B—98.4%
- Pfizer CentreOne$382M—1.6%
Forward guidance
Pfizer provided its 2022 financial guidance, including revenue expectations between $98.0 to $102.0 billion and adjusted diluted EPS of $6.35 to $6.55.
Tailwinds
- Midpoint of revenue guidance represents 23% growth from 2021 revenues.
- Includes anticipated $32 billion of revenue for Comirnaty.
- Includes anticipated $22 billion of revenue for Paxlovid.
- Midpoint of adjusted diluted EPS guidance reflects a 46% increase over 2021 actual results.
- Change in policy for intangible amortization expense is estimated to benefit adjusted diluted EPS by approximately $0.06.
Headwinds
- Assumes no completion of any business development transactions not completed as of December 31, 2021.
- Reflects an anticipated negative revenue impact of $0.7 billion due to recent and expected generic and biosimilar competition.
- Financial guidance reflects the anticipated unfavorable impact of approximately $1.1 billion on revenues and approximately $0.06 on Adjusted diluted EPS as a result of changes in foreign exchange rates.
- Guidance for Adjusted diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.8 billion shares, which assumes no share repurchases in 2022.
- Expected increase in weighted average shares outstanding compared to 2021 of approximately 100 million shares has an unfavorable impact on 2022 Adjusted diluted EPS of $0.10.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-0.3%
Avg return
Earnings day
-0.3%
Avg return
5 days after
+0.1%
Avg return
30 days after
50%
36 / 72 earnings
Positive
+8.1%
Q1 2024
Best reaction
-10.0%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | -2.5% | -2.3% | |
| Q4 2025 | -3.3% | +2.1% | -0.2% | |
| Q3 2025 | -1.5% | -0.9% | +4.2% | |
| Q1 2025 | +3.2% | +5.0% | +1.7% | |
| Q4 2024 | -1.3% | -1.8% | +0.2% | |
| Q3 2024 | -1.2% | -2.7% | -10.5% | |
| Q2 2024 | -0.6% | -0.9% | -6.5% | |
| Q1 2024 | +8.1% | +9.9% | +11.9% | |
| Q4 2023 | -1.5% | -2.0% | -3.3% | |
| Q3 2023 | -0.1% | +2.3% | -0.3% | |
| Q2 2023 | -2.0% | -2.9% | -1.9% | |
| Q1 2023 | -1.9% | -1.8% | -3.0% | |
| Q4 2022 | +1.0% | +1.2% | -6.7% | |
| Q3 2022 | +1.1% | +1.4% | +9.7% | |
| Q2 2022 | -2.8% | -4.4% | -9.9% | |
| Q1 2022 | +2.7% | +1.4% | +9.0% | |
| Q4 2021 | -3.3% | -4.6% | -7.5% | |
| Q3 2021 | +2.7% | +11.4% | +21.5% | |
| Q2 2021 | +1.6% | +4.4% | +10.7% | |
| Q1 2021 | +0.4% | -0.6% | -2.2% | |
| Q4 2020 | -2.7% | -2.5% | -4.5% | |
| Q3 2020 | -6.5% | -6.4% | +1.5% | |
| Q2 2020 | +4.6% | +2.5% | +0.9% | |
| Q1 2020 | -0.5% | -1.8% | -0.4% | |
| Q4 2019 | -6.4% | -7.3% | -15.1% | |
| Q3 2019 | +3.2% | +3.0% | +3.6% | |
| Q2 2019 | -10.0% | -11.8% | -18.6% | |
| Q1 2019 | +3.0% | +4.5% | +5.8% | |
| Q4 2018 | +5.2% | +8.5% | +9.7% | |
| Q3 2018 | -0.4% | -0.7% | +5.3% | |
| Q2 2018 | +4.3% | +5.1% | +7.5% | |
| Q1 2018 | -4.7% | -4.8% | -1.9% | |
| Q4 2017 | -5.1% | -6.2% | -8.7% | |
| Q3 2017 | +0.3% | +1.1% | +3.2% | |
| Q2 2017 | -0.7% | +1.4% | +2.3% | |
| Q1 2017 | -0.9% | -0.9% | -3.2% | |
| Q4 2016 | +1.1% | +2.5% | +10.2% | |
| Q3 2016 | -3.4% | -5.4% | -0.8% | |
| Q2 2016 | -5.4% | -5.0% | -7.0% | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | -1.6% | — | — | |
| Q3 2015 | +3.8% | — | — | |
| Q2 2015 | +4.1% | — | — | |
| Q1 2015 | -0.9% | — | — | |
| Q4 2014 | -2.6% | — | — | |
| Q3 2014 | +1.6% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | -4.3% | — | — | |
| Q4 2013 | +1.5% | — | — | |
| Q3 2013 | +0.6% | — | — | |
| Q2 2013 | -1.0% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2012 | +2.5% | — | — | |
| Q3 2012 | -1.3% | — | — | |
| Q2 2012 | +0.9% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | -0.6% | — | — | |
| Q3 2011 | +3.4% | — | — | |
| Q2 2011 | +4.8% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2010 | +1.5% | — | — | |
| Q3 2010 | -1.4% | — | — | |
| Q2 2010 | +0.5% | — | — | |
| Q1 2009 | -4.1% | — | — | |
| Q1 2010 | -1.1% | — | — | |
| Q4 2007 | +0.4% | — | — | |
| Q4 2009 | +0.4% | — | — | |
| Q3 2008 | +0.2% | — | — | |
| Q3 2009 | +0.2% | — | — | |
| Q4 2008 | +0.6% | — | — | |
| Q2 2008 | +0.6% | — | — | |
| Q2 2009 | +0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro